Advertisement

Urolithiasis

, Volume 46, Issue 6, pp 573–579 | Cite as

The risk of bladder cancer in patients with urinary calculi: a meta-analysis

  • Zhang Yu
  • Wu Yue
  • Li Jiuzhi
  • Jiang Youtao
  • Zhang Guofei
  • Guo Wenbin
Review

Abstract

The objective of this meta-analysis was to evaluate the association between a history of urinary calculi (UC) and the risk of bladder cancer (BC). A literature search was performed from inception until July 2017. Studies that reported odds ratios (OR), relative risks or hazard ratios comparing the risk of BC in patients with the history of UC vs those without the history of UC were included. Pooled odds ratios and 95% confidence interval (CI) were calculated using a random-effect or fixed-effect method. Thirteen studies were included in our analysis to assess the association between a history of UC and risk of BC. The pooled OR of BC in patients with UC was 1.87 (95% CI, 1.45–2.41). Bladder calculi [OR, 2.17 (95% CI, 1.52–3.08)] had a higher risk of BC than kidney calculi [OR, 1.39 (95% CI, 1.06–1.82)]. The subjects had a history of UC that was associated with increased BC risk both in males [OR, 2.04 (95% CI, 1.41–2.96)] and in females [OR, 2.99 (95% CI, 2.37–3.76)]. The subgroup analysis demonstrated that UC increasing risk of BC both in case-control studies [OR, 1.75 (95% CI, 1.25–2.45)] and cohort studies [OR, 2.27 (95% CI, 1.55–3.32)]. The pooled OR of BC risk in patients with UC were 1.60 (95% CI, 1.15–2.24) in America, 1.36 (95% CI, 1.14–1.64) in Europe and 3.05 (95% CI, 2.21–4.21) in Asia, respectively. Our study demonstrates a significant increased risk of BC in patients with prior UC. This finding suggests that a history of UC is associated with BC and may impact clinical management and cancer surveillance. Further studies still needed to confirm the findings.

Keywords

Urinary calculi Bladder cancer Risk Meta-analysis 

Notes

Acknowledgements

The authors thank Jun Zhou for his assessment of the statistics to the revised manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.

References

  1. 1.
    Burin GJ, Gibb HJ, Hill RN (1995) Human bladder cancer: evidence for a potential irritation-induced mechanism. Food Chem Toxicol 33:785–795CrossRefGoogle Scholar
  2. 2.
    Chow WH, Lindblad P, Gridley G, Nyren O, McLaughlin JK, Linet MS, Pennello GA, Adami HO, Fraumeni JJ (1997) Risk of urinary tract cancers following kidney or ureter stones. J Natl Cancer Inst 89:1453–1457CrossRefGoogle Scholar
  3. 3.
    Chung SD, Tsai MC, Lin CC, Lin HC (2013) A case-control study on the association between bladder cancer and prior bladder calculus. BMC Cancer 13:117CrossRefGoogle Scholar
  4. 4.
    Cohen SM, Johansson SL, Arnold LL, Lawson TA (2002) Urinary tract calculi and thresholds in carcinogenesis. Food Chem Toxicol 40:793–799CrossRefGoogle Scholar
  5. 5.
    Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860–867CrossRefGoogle Scholar
  6. 6.
    Dobruch J, Daneshmand S, Fisch M, Lotan Y, Noon AP, Resnick MJ, Shariat SF, Zlotta AR, Boorjian SA (2016) Gender and bladder cancer: a collaborative review of etiology, biology, and outcomes. Eur Urol 69:300–310CrossRefGoogle Scholar
  7. 7.
    Dunham LJ, Rabson AS, Stewart HL, Frank AS, Young JL (1968) Rates, interview, and pathology study of cancer of the urinary bladder in New Orleans, Louisiana. J Natl Cancer Inst 41:683–709PubMedGoogle Scholar
  8. 8.
    Gonzalez CA, Errezola M, Izarzugaza I, Lopez-Abente G, Escolar A, Nebot M, Riboli E (1991) Urinary infection, renal lithiasis and bladder cancer in Spain. Eur J Cancer 27:498–500CrossRefGoogle Scholar
  9. 9.
    Guo Y, Xu F, Lu T, Duan Z, Zhang Z (2012) Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 38:904–910CrossRefGoogle Scholar
  10. 10.
    Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558CrossRefGoogle Scholar
  11. 11.
    Jacobs BL, Lee CT, Montie JE (2010) Bladder cancer in 2010: how far have we come? CA Cancer J Clin 60:244–272CrossRefGoogle Scholar
  12. 12.
    Jhamb M, Lin J, Ballow R, Kamat AM, Grossman HB, Wu X (2007) Urinary tract diseases and bladder cancer risk: a case-control study. Cancer Causes Control 18:839–845CrossRefGoogle Scholar
  13. 13.
    Johansson SL, Cohen SM (1997) Epidemiology and etiology of bladder cancer. Semin Surg Oncol 13:291–298CrossRefGoogle Scholar
  14. 14.
    Kantor AF, Hartge P, Hoover RN, Narayana AS, Sullivan JW, Fraumeni JR JF (1984) Urinary tract infection and risk of bladder cancer. Am J Epidemiol 119:510–515CrossRefGoogle Scholar
  15. 15.
    Kjaer SK, Knudsen JB, Sorensen BL, Moller JO (1989) The Copenhagen case-control study of bladder cancer. V. Review of the role of urinary-tract infection. Acta Oncol 28:631–636CrossRefGoogle Scholar
  16. 16.
    Leal J, Luengo-Fernandez R, Sullivan R, Witjes JA (2016) Economic burden of bladder cancer across the European Union. Eur Urol 69:438–447CrossRefGoogle Scholar
  17. 17.
    Letasiova S, Medve’Ova A, Sovcikova A, Dusinska M, Volkovova K, Mosoiu C, Bartonova A (2012) Bladder cancer, a review of the environmental risk factors. Environ Health 11(Suppl 1):S11CrossRefGoogle Scholar
  18. 18.
    Lin CL, Huang WT, Fan WC, Feng YH, Lin CH, Lin CS, Lu CC, Cheng TC, Tsao CJ, Lin SH (2016) Associations between interventions for urolithiasis and urinary tract cancer among patients in Taiwan: the effect of early intervention. Medicine (Baltimore) 95:e5594CrossRefGoogle Scholar
  19. 19.
    Long LO, Park S (2007) Update on nephrolithiasis management. Minerva Urol Nefrol 59:317–325PubMedGoogle Scholar
  20. 20.
    Lopez M, Hoppe B (2010) History, epidemiology and regional diversities of urolithiasis. Pediatr Nephrol 25:49–59CrossRefGoogle Scholar
  21. 21.
    Miano R, Germani S, Vespasiani G (2007) Stones and urinary tract infections. Urol Int 79(Suppl 1):32–36CrossRefGoogle Scholar
  22. 22.
    Michaud DS (2007) Chronic inflammation and bladder cancer. Urol Oncol 25:260–268CrossRefGoogle Scholar
  23. 23.
    Munafo MR, Flint J (2004) Meta-analysis of genetic association studies. Trends Genet 20:439–444CrossRefGoogle Scholar
  24. 24.
    Nesi G, Nobili S, Cai T, Caini S, Santi R (2015) Chronic inflammation in urothelial bladder cancer. Virchows Arch 467:623–633CrossRefGoogle Scholar
  25. 25.
    Shakhssalim N, Hosseini SY, Basiri A, Eshrati B, Mazaheri M, Soleimanirahbar A (2010) Prominent bladder cancer risk factors in Iran. Asian Pac J Cancer Prev 11:601–606PubMedGoogle Scholar
  26. 26.
    Shih CJ, Chen YT, Ou SM, Yang WC, Chen TJ, Tarng DC (2014) Urinary calculi and risk of cancer: a nationwide population-based study. In e342Google Scholar
  27. 27.
    Sturgeon SR, Hartge P, Silverman DT, Kantor AF, Linehan WM, Lynch C, Hoover RN (1994) Associations between bladder cancer risk factors and tumor stage and grade at diagnosis. Epidemiology 5:218–225CrossRefGoogle Scholar
  28. 28.
    Tao L, Qiu J, Jiang M, Song W, Yeh S, Yu H, Zang L, Xia S, Chang C (2016) Infiltrating T cells promote bladder cancer progression via increasing IL1–>androgen receptor–>HIF1alpha–>VEGFa signals. Mol Cancer Ther 15:1943–1951CrossRefGoogle Scholar
  29. 29.
    Tavani A, Fioretti F, La Vecchia C, Franceschi S (1998) Re: risk of urinary tract cancers following kidney or ureter stones. J Natl Cancer Inst 90:250–251CrossRefGoogle Scholar
  30. 30.
    Wynder EL, Onderdonk J, Mantel N (1963) An epidemiological investigation of cancer of the bladder. Cancer 16:1388–1407CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of UrologyBao An Central Hospital of Shen ZhenShen ZhenChina
  2. 2.Department of Urologythe Sixth Affiliated Hospital of Xin Jiang Medical UniversityUrumqiChina
  3. 3.People’s Hospital of Xin Jiang Uygur Autonomous RegionUrumqiChina
  4. 4.Department of UrologyThe Third Affiliated Hospital of Southern Medical UniversityGuangzhouChina

Personalised recommendations